In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection  by Day, Patricia M. et al.
Cell Host & Microbe
ArticleIn Vivo Mechanisms of Vaccine-Induced
Protection against HPV Infection
Patricia M. Day,1,4 Rhonda C. Kines,1,4 Cynthia D. Thompson,1 Subhashini Jagu,2 Richard B. Roden,2,3
Douglas R. Lowy,1 and John T. Schiller1,*
1Laboratory of Cellular Oncology, NCI, National Institutes of Health, Bethesda, MD 20892, USA
2Department of Pathology
3Department of Oncology Gynecology and Obstetrics
Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
4These authors contributed equally to this work
*Correspondence: schillej@dc37a.nci.nih.gov
DOI 10.1016/j.chom.2010.08.003SUMMARY
Using a human papillomavirus (HPV) cervicovaginal
murine challenge model, we microscopically exam-
ined the in vivo mechanisms of L1 virus-like particle
(VLP) and L2 vaccine-induced inhibition of infection.
In vivo HPV infection requires an initial association
with the acellular basement membrane (BM) to
induce conformational changes in the virion that
permit its association with the keratinocyte cell
surface. By passive transfer of immune serum, we
determined that anti-L1 antibodies can interfere
with infection at two stages. Similarly to active VLP
immunization, transfer of high L1 antibody concen-
trations prevented BMbinding. However, in the pres-
ence of low concentrations of anti-L1, virions associ-
ated with the BM, but to the epithelial cell surface
was not detected. Regardless of the concentration,
L2 vaccine-induced antibodies allow BM association
but prevent association with the cell surface. Thus,
we have revealed distinct mechanisms of vaccine-
induced inhibition of virus infection in vivo.INTRODUCTION
Papillomaviruses (PVs) are a family of small, nonenveloped
viruses that encapsidate an 8 kb double-stranded circular DNA
genome. More than 100 HPV genotypes (types) have been
described, with each type being classified based primarily on
differences in the amino acid sequence of the major capsid
protein, L1 (Bernard et al., 2010; de Villiers et al., 2004). The virus
capsid also contains the minor protein, L2, whose N-terminal
domain is highly conserved among the PV family (Gambhira
et al., 2007; Pereira et al., 2009). Human papillomaviruses
(HPVs) are the primary etiological agents involved in the develop-
ment of cervical neoplasia. More than 10 HPV types can cause
cervical cancer, with HPV16 and HPV18 accounting for 70%
of cases (Mun˜oz et al., 2004; Schiffman et al., 2007). HPVs
have also been implicated as a causative agent of other260 Cell Host & Microbe 8, 260–270, September 16, 2010 ª2010 Elsano-genital and oropharyngeal cancers, aswell as benign genital
and cutaneous warts (Giuliano et al., 2008).
L1 can self-assemble into virus-like particles (VLPs)
comprised of 72 pentameric capsomers. L1 VLPs contain
immunodominant epitopes that elicit strong type-specific
immune responses capable of inhibiting PV infection in animal
model systems (Breitburd et al., 1995; Christensen et al., 1996;
Kirnbauer et al., 1992; Suzich et al., 1995). Virion-binding
antibodies are thought to act as the primary mechanism for
inhibition, as passively-administered sera from animals vacci-
nated with VLPs from the cottontail rabbit papillomavirus
(CRPV) and canine oral papillomavirus (COPV) confer protection
against type-specific challenge (Breitburd et al., 1995; Suzich
et al., 1995). The strong immunogenicity of L1 has led to
the development of two commercial L1 VLP-based vaccines:
Cervarix, a bivalent vaccine targeting HPV16/18 (Paavonen
et al., 2009), and Gardasil, a quadrivalent formulation consisting
of VLPs of HPV6/11/16/18 (Mun˜oz et al., 2010) (HPV6 andHPV11
cause most cases of genital warts). Both vaccines are highly
effective at preventing infection and neoplastic lesions caused
by the targeted HPV types. The immunity generated by L1 VLP
vaccination is PV type restricted due to sequence divergence
in the surface loops of the L1 capsid proteins among PV types
(Carter et al., 2006). In contrast, the minor capsid protein, L2,
has recently been recognized as an attractive alternative vaccine
target, due to the evidence that, when removed from its normal
context in the virion, the highly conserved N-terminal region of
L2 contains epitope(s) capable of generating broadly cross-
type neutralizing antibodies (Gambhira et al., 2007; Jagu et al.,
2009; Roden et al., 2000).
Elucidation of the mechanisms that underlie vaccine-induced
protection can provide insight into the effectiveness of the
currently licensed vaccines and assist in the assessment and
design of future vaccines, including those based on L2. The
mechanisms whereby vaccine-induced antibodies prevent
infection are reasonably well understood for a number of viruses
in cultured cell systems. By contrast, knowledge of how anti-
virion antibodies prevent infection in vivo is limited because
few animal models of virus binding, entry, and infection have
been extended to a microscopic examination of the relevant
tissue (Miller et al., 2005; Ong et al., 2008). Mechanisms of
in vivo inhibition of virus infection could be particularly informa-
tive for HPV vaccines that target L1 or L2, as we have recentlyevier Inc.
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cultured cells and that observed in vivo utilizing amurine cervico-
vaginal challenge (CVC) model (Kines et al., 2009; Roberts et al.,
2007). The CVC model and analysis of the infectious steps were
made possible by development of high-titer HPV pseudovirions
(PsV) in which the authentic L1 and L2 capsid proteins encapsi-
date a reporter plasmid (e.g., luciferase). Expression of the
reporter gene can be used as a surrogate for virus infection
(Buck and Thompson, 2007). The pseudovirions have been
well characterized and are believed to behave similarly to
authentic virus during the establishment phase of the infectious
process (Day et al., 2004; Florin et al., 2004; Gambhira et al.,
2007). These properties make them well suited for examination
of the early events in PV infection.
Whereas the initial steps in HPV infection can occur on the
surface of immortalized cultured cell lines, the in vivo CVCmodel
has shown that, remarkably, the earliest steps in HPV infection
occur strictly on the acellular basement membrane (BM) prior
to transfer of the virion to its target epithelial cell, the keratinocyte
(Kines et al., 2009; Roberts et al., 2007). The initial step in in vivo
infection is binding of the virion to BM heparan sulfate proteogly-
cans (HSPG) at sites exposed due to epithelial damage. This
step, which is L1 dependent but L2 independent, is followed
by a conformational change in the capsid that renders the L2 N
terminus susceptible to proprotein convertase (PC) cleavage
(furin and/or PC5/6). PC cleavage leads to exposure of a major
N-terminal cross-neutralization epitope on L2 (aa 17–36) as
well as exposure of a previously occluded region of L1, resulting
in virion transfer and stable association with an undetermined
receptor on the epithelial cell surface. By comparison, in cultured
cells, PsV bind avidly to cell surface HSPG followed by PC
cleavage of L2 and exposure of the L2 cross-neutralization
epitope on the cell surface (Day et al., 2007). The pseudovirions
subsequently bind to a second, undetermined receptor, also
located on the cell surface (Day et al., 2008). PsV can also bind
to the extracellular matrix (ECM) produced by cultured cells.
However, ECM binding is not equivalent to in vivo BM binding
in that ECM binding is largely independent of HSPG interaction
and does not result in efficient cleavage of L2. Therefore, in
cultured cells, the key early steps in infection take place on the
cell surface, whereas in the murine CVC model, as discussed
above, the steps are spatially separate, with initial HSPG binding
and PC cleavage occurring on the BM prior to transfer to the
epithelial cell surface.
The above differences make it difficult to predict the in vivo
mechanisms by which the antibodies induced by L1 VLP- and
L2-based vaccines act to prevent infection. Therefore, we have
undertaken an analysis of the protection induced by both of
these vaccines in the CVC model and correlated protection
with the infectious steps abrogated by vaccination or passive
transfer of vaccine-induced antibodies.
RESULTS
Vaccination with HPV16 L1 VLPs Induces
Type-Restricted Protection in the Mouse CVC Model
To examine the type specificity of L1 VLP-induced protection
from cervicovaginal challenge, mice were vaccinated with either
alum alone or HPV16 L1 VLPs (precipitated onto alum) threeCell Host &times at 2 week intervals and then vaginally challenged, 2 weeks
after the final immunization, with 10 mg of HPV pseudovirions of
types 16, 31, 45, or 58 (Figures 1A–1D). Antibodies generated
after VLP vaccination are type restricted in their ability to
neutralize virus in vitro (Christensen and Kreider, 1990; Giroglou
et al., 2001; Pastrana et al., 2004), and the HPV16 L1 VLPs
induced strong protection against HPV16 vaginal challenge
(100%, p = 0.0012, Figure 1A). HPV16, 31, and 58 are phyloge-
netically grouped in the a9 species (Bernard et al., 2010), with
16 being more closely related to 31 than to 58, and this corre-
lated with the partial protection observed against HPV31
(57.3%, p = 0.0826, Figure 1B) and lack of protection against
HPV58 (NS, Figure 1D). In the mice challenged with HPV58,
the notable difference in the radiance between the HPV16
VLP-vaccinated and alum-vaccinated control was driven by
outliers in the VLP group and was not significant. HPV45 is
even more divergent from HPV16, as it is a member of the a7
species, which also includes HPV18. This divergence correlates
with the lack of protection from HPV45 infection after 16L1 VLP
vaccination (NS, Figure 1C). Importantly, the results in the CVC
model are qualitatively similar to the protection against the a9
species seen in women in the clinical efficacy trials of the
commercial vaccines for protection against 6 months persistent
infection. It was found that women who were given either of the
commercial vaccines were strongly protected against HPV16,
partially protected against HPV31, and not protected against
HPV58 (the HPV45 results in women cannot be readily
compared, as the commercial vaccines also contain VLPs from
HPV18, which, as noted above, is an a7 species virus) (Brown
et al., 2009; Paavonen et al., 2009). Thus, the murine model is
capable of recapitulating the protection observed in vaccinated
women.
HPV Virion Localization In Vivo after Vaccination
with HPV16 L1 VLPs
To identify at which step HPV16 L1 VLP vaccination interferes
with viral infection, vaccinated mice were vaginally challenged
with either HPV16 or HPV45 PsV, which were labeled with Alexa
Fluor 488 (AF488). AF488-coupled PsV have been utilized in
previous in vivo studies and have binding (Kines et al., 2009)
and infectivity (Roberts et al., 2007) profiles similar to unmodified
PsV, which were used in the experiment in Figure 1. We opted to
utilize AF488-coupled PsV for the binding analysis to facilitate
virion detection in the presence of vaccine-induced anti-L1
antibodies.
Tissues were harvested at either 4 or 18 hr following PsV
challenge, and the localization of the capsids was determined.
In alum-treated mice, as predicted from previous work in naive
mice (Kines et al., 2009), both the HPV16 and HPV45 capsids
initially localized to the exposed BM (Figures 2A and 2D), the
L2 17–36 epitope was readily detected at the 4 hr time point after
virus challenge (Figures 2B and 2E), and by 18 hr, some virions
were associated with the surface of the re-epithelializing cellular
layer, although some residual virions on the BM were clearly
visible (Figures 2C, 2F, and 2L), as previously reported (Kines
et al., 2009). By contrast, in mice vaccinated with HPV16 L1
VLPs and challenged with HPV16 PsV, the viral capsids never
associated with the BM. Instead, 4 hr after HPV16 challenge,
the capsids were found associated with large cellular aggregatesMicrobe 8, 260–270, September 16, 2010 ª2010 Elsevier Inc. 261
Figure 1. Protection from Infection after
HPV16 L1 VLP or L2 11–88x5 Vaccination
Mice were vaccinated with Alum only (solid bars),
5 mg HPV16 L1 VLPs,VLPs (A–D), or 25 mg L2
11–88x5 (E–H) (hatched bars) and challenged
with (A and E) HPV16, (B and F) HPV31, (C and
G) HPV45 or (D and H) HPV58. Unvaccinated
mice were challenged with vehicle only (CMC,
open bars) to establish background lumines-
cence. Values on the y axis are average radiance
(p/s/cm2/sr). Data represent the mean ± SEM of
five mice/group from a representative experiment.
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investigation determined that the cellular aggregates were
primarily comprised of neutrophils, and the antibody/virus
complex was found predominantly on these cells (Figure 3B).
The capsids also bound neutrophils in alum-immunized mice
(Figure 3A), although to a lesser extent, indicating that this inter-
action can occur in the absence of virion-specific antibodies. The
L2 17–36 epitope was undetectable (Figure 2H) at 4 hr, and by
18 hr, the amount of detectable virus was greatly decreased to
near background levels (Figure 2I), possibly due to degradation
by the neutrophils. The above changes were specific for262 Cell Host & Microbe 8, 260–270, September 16, 2010 ª2010 Elsevier Inc.HPV16 L1 VLP-induced protection, as
the HPV16-vaccinated mice challenged
with HPV45 displayed virion localization
and L2 epitope exposure similar to that
of alum-treated mice, which correlated
with the lack of protection against
HPV45 (Figures 2J–2L).
Prevention of BM Binding
by Passive Transfer of anti-HPV16
L1 Immune Serum Is Antibody
Concentration Dependent
As noted earlier, transfer of immune
serum from L1 VLP vaccinees to naive
recipients as a means of passive immuni-
zation can confer protection in animal PV
models. We decided to verify this with our
vaccination protocol and to confirm that
the observed effects on PsV binding
utilizing the CVC model following VLP-
vaccination can be attributed solely to
the induced antibodies. Therefore, we
passively transferred high-titer serum
from a rabbit immunized with HPV16 L1
VLPs into naive mice. As expected, the
passive transfer of a high serum volume
(20 ml) resulted in strong protection
(>99.9%, p = 0.0026) against HPV16
PsV challenge and no protection from
infection with HPV45 (Figures S1A and
S1B available online). Microscopic anal-
ysis of tissue from mice challenged with
HPV16 revealed a pattern of rabbit
antibody-bound PsV identical to the PsVpattern seen following vaccination. This included the lack of
BM binding at 4 hr (Figure 4C), association of the antibody-PsV
complexes with lumenal neutrophils (Figure 3C), and greatly
diminished amounts of detectable virus at 18 hr (Figure 4D).
Passive transfer of preimmune rabbit serum gave results that
were similar to the alum-immunized controls (Figures 4A and
4B). Because there is no formation of antibody-capsid
complexes in the presence of preimmune serum (Figure 4A),
we demonstrate the presence of PsV with anti-HPV16 L1
staining (Figure 4B). In addition, the BM deposition of HPV45
virus in the presence of the high-volume anti-16 L1 serum was
Figure 2. PsV Capsid Localization and L2
Exposure following VLP Immunization
(A–C) Pseudovirion capsids were evaluated for
their ability to interact with the BM and epithelium
and expose the L2 cross-neutralization epitope
following generation of an antibody response via
immunization with either adjuvant only or HPV16
VLPs and adjuvant. HPV16 pseudovirions in tissue
from alum-immunized animals are shown in (A–C).
(A) and (C) show the localization of AF488-coupled
capsids (green) at 4 hr and 18 hr, respectively. (B)
shows the exposure of the L2 17–36 epitope at 4 hr
following delivery of uncoupled pseudovirions,
detected with a rabbit polyclonal antiserum
against L2 aa 17/36 (green).
(D–F) Detection of HPV45 capsids is shown.
AF488-coupled capsids are shown in (D) and (F)
at 4 hr and 18 hr, respectively. The L2 epitope
exposure at 4 hr is shown in (E).
(G–L) The remaining panels show the analogous
experiments performed in the VLP-immunized
animals. HPV16 pseudovirion detection is shown
in (G–I). Capsid binding is shown for the two time
points in (G) and (I). L2 epitope exposure at 4 hr
is shown in (H). HPV45 pseudovirus binding is
shown in (J–L). Capsid association is in (J) and
(L) at 4 hr and 18 hr. L2 exposure is in (K). Images
are representative of five animals tested for each
condition examined.
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evidence for type-specific immunity (data not shown). These
data verify that serum antibodies can account for all of themicro-
scopic findings observed in the mice protected by HPV16 VLP
vaccination.
It is known that vaccine-induced antibodies wane over time in
vaccine subjects (Olsson et al., 2007; Romanowski et al., 2009).
Therefore, we wanted to examine protection from infection and
mechanisms of inhibition in the presence of low amounts of
circulating anti-HPV16 L1 VLP antibodies. We performed
a microscopic examination of tissue from mice that were sub-
jected to an HPV16 PsV challenge following passive transfer of
the lowest volume of the immune rabbit serum (0.2 ml) that was
still highly protective from type-specific challenge (>97%, p =
0.0029) (Figure S1A). (The transfer of one-half as much volume
(0.1 ml) resulted in only 90% protection [R.C.K., unpublished
data]). When the 0.2 ml volume was transferred, the microscopicCell Host & Microbe 8, 260–270, Seappearance following HPV16 PsV chal-
lenge differed substantially from what
had been observed above with the higher
volume (20 ml). The most striking differ-
ence was that, at the 4 hr time point, the
input HPV16 PsV could be found associ-
ated with the BM (Figure 4E). This pattern
of deposition was qualitatively similar to
that found in control tissues of mice that
received preimmune serum, albeit pre-
sent at substantially reduced levels. To
confirm that this staining truly repre-
sented association with the BM, we ex-
amined the colocalization of the capsidswith nidogen, a marker of the BM (Figures S2A and S2B). In
addition, we determined that the L2 17–36 epitope was exposed
on these BM-bound capsids at 4 hr (Figure 4G; Figure 4H shows
complete blocking of passively transferred antibody prior to
immune detection of L2). Substantial binding of virions by
neutrophils was also evident at 4 hr (Figure 3D). However,
when we examined tissues harvested at the 18 hr time point,
we were unable to detect bound PsV, indicating loss of particles
from the BM and lack of stable association with the epithelial cell
surface (Figure 4F). Thus, the lower volume of immune serum did
not completely prevent BM binding or L2 epitope exposure,
although it did completely abrogate infection. This result
indicates that an additional mechanism of neutralization is
evident at lower antibody concentrations. As observed with
the high-volume anti-16L1 sera transfer, HPV45 binding was
unaffected by low volume transfer and was similar to controls
(data not shown).ptember 16, 2010 ª2010 Elsevier Inc. 263
Figure 3. Colocalization of Pseudovirus with Neutrophils
(A–D) HPV16 pseudovirus was instilled into the vaginal tract of an alum-vacci-
natedmouse (A), an HPV16 VLP-vaccinatedmouse (B), or amice that received
passively transferred rabbit anti-L1 immune serum (C, high volume, and D, low
volume). Alexa Fluor 488-coupled pseudovirus (green) was used in the animals
shown in (A) and (B). In (C) and (D), the antibody-bound pseudovirus was
detected with Alexa Fluor 488-coupled donkey anti-rabbit secondary antibody
(green). BM-associated virions evident in (D) are indicated with the arrow.
Neutrophils were detected in all panels with a rat anti-neutrophil antibody
and Alexa Fluor 594-coupled donkey anti-rat secondary antibody (red). All
tissues were harvested at 4 hr postinstillation. Images are representative of
five animals tested for each condition examined.
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lower volumes of immune serum prompted us to ask whether
similar observations might be made in cultured cells. We found
that, at both the high concentration and the low concentration
of serum that inhibited infection of cultured cells (data not
shown), the PsV was prevented from binding to the ECM but
bound robustly to the cell surface, unlike what was seen in vivo
(Figures S3E and S3F). We suspect that PsV/antibody
complexes bind to HSPG determinants on the cells because
the complexes did not bind pgsa-745 cells, which lack all
GAGs due to a mutation in a processing enzyme, or to sodium
chlorate-treated HaCaT cells, which express undersulfated
HSPG (P.M.D., unpublished data). However, exposure of the
L2 epitope did correlate with the in vivo observations, in that it
was not exposed at high-serum concentrations but became
exposed at low concentrations (compare Figures S3C and S3D
with Figure 4G).
In Vivo Protection from Infection after Vaccination
with HPVL2 11–88x5
We also examined the protection elicited by an L2-based
vaccine and studied its mechanism of protection. We used
a candidate L2 vaccine consisting of a single polypeptide, desig-
nated L2 11–88x5, which is composed of the conserved264 Cell Host & Microbe 8, 260–270, September 16, 2010 ª2010 ElsN-terminal sequence of amino acids 11–88 from the L2 of the
distantly related HPV types 1, 5, 6, 16, and 18. L2 11–88x5 can
induce cross-neutralizing antibodies both in mice and rabbits,
as determined by a tissue culture-based neutralization assay,
and can protect mice against cutaneous challenge with HPV16
PsV (Jagu et al., 2009). To determine whether broad cross-
protection occurs in the CVC in vivo model, we vaccinated
mice with alum alone or L2 11–88x5 (precipitated onto alum)
three times at 2 week intervals and subsequently vaginally
challenged them with HPV types 16, 31, 45, and 58 2 weeks
following the final immunization (Figures 1E–1H). We observed
99.9% (p = 0.0278), 90.4% (p < 0.0001), 100% (p = 0.0993),
and 99.7% (p = 0.0272) inhibition of infection, respectively, indi-
cating that effective cross-protection against cervicovaginal
infection was generated. It is noteworthy that the L2 11–88x5
vaccine induced good protection against HPV31, HPV45, and
HPV58, although none of these HPV types is present in the
immunogen.
HPV Capsid Localization In Vivo after Vaccination
with L2 11–88x5
The substantial in vivo cross-protection induced by L2 11–88x5
vaccination prompted us to examine at which step antibodies
raised to this immunogen interfere with the infectious process.
Given that the L2 cross-neutralization epitope is not exposed
until after the virus has bound to the BM, it seemed unlikely
that these antibodies would prevent BM binding. Indeed,
following vaccination with L2 11–88x5 and vaginal challenge
with HPV16 or HPV45, capsids of both HPV types localized
on the BM at 4 hr, as determined by staining with an anti-L1
antibody (Figures 5A and 5C). Unexpectedly, by 18 hr, both
HPV16 and HPV45 capsids were undetectable on the BM or
elsewhere in the tissue (Figures 5B and 5D). Unfortunately, inter-
ference from vaccine-induced antibodies prevented us from
directly monitoring the L2 epitope exposure in these mice.
However, as L2 17–36 exposure is detectable by 4 hr, it seems
likely that exposure occurs as in control animals, which would
enable the vaccine-induced L2 antibodies to bind to the
epitope(s) that becomes exposed on the BM. This antibody
engagement appears to lead to the premature separation of
the virus from the BM and its failure to stably bind the epithelial
cells.
L2 Antibodies Induced by L2 11–88x5 Vaccination
Prevent the Stable Engagement of BM-Bound Virus
with Epithelial Cells
Most of the above speculation could be tested by passive
transfer of immune sera from L2 11–88x5-vaccinated animals.
Therefore, we transferred a high volume (100 ml) and a low
volume (20 ml) of immune rabbit serum into naive mice to assess
protection from infection by HPV16 and HPV45 PsV. In addition,
we microscopically evaluated viral localization events associ-
ated with this challenge (Figure 6). Passive transfer of 100 ml
immune serum protected the mice from both HPV16 and
HPV45 PsV challenge by 100% (p = 0.0035 and p < 0.0001,
respectively), and transfer of 20 ul immune serum completely
protected them from HPV16 (99.6%, p = 0.0036) and, to a lesser
degree, HPV45 (90%, p = 0.0003) (Figures S1C and S1D).
Following challenge with either HPV type, the microscopicevier Inc.
Figure 4. Localization of Capsids following Passive Transfer of
Anti-VLP Sera
Either preimmune or rabbit anti-HPV16 VLP immune sera was passively
transferred into mice, and the localization of capsids was analyzed at either
4 or 18 hr following delivery. The capsid-antibody complexes were detected
with Alexa Fluor 488-conjugated donkey anti-rabbit (green).
(A and B) Detection of binding of preimmune sera at 4 hr is shown in (A).
Detection of capsids in the same tissue with an anti-HPV16 L1 serum is shown
in (B).
(C and D) Detection of capsid-antibody complexes following the transfer of
a high volume of immune serum is shown in (C) (4 hr) and (D) (18 hr).
(E and F) Detection of capsid-antibody complexes following the transfer of
a low volume of immune serum is shown in (E) (4 hr) and (F) (18 hr).
(G and H) Detection of exposure of L2 following low-volume passive transfer is
shown in (G) (4 hr). This detection required blocking the passively transferred
rabbit serum with unlabeled donkey anti-rabbit serum prior to binding of the
Cell Host & Microbe
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Cell Host &observations, as determined by detection of rabbit antibody-
bound-PsV complexes, were indistinguishable, irrespective of
the volume of serum transferred, from what had been observed
in the mice immunized with L2 11–88x5. This includes BM
binding at 4 hr postchallenge (HPV16 Figures 6A, 6B, 6D, 6E;
HPV45 Figures 6G, 6H, 6K) and loss of both HPV16 and
HPV45 by 18 hr (Figures 6C, 6F and 6I, 6L, respectively). The
presence of anti-L2 antibody bound to HPV45 at 4 hr was below
the level of detection in the presence of low-serumpassive trans-
fer (Figure 6J); however, we could visualize virions on the BM
with an anti-L1 antibody (Figure 6K). Thus, the protection medi-
ated by L2 11–88x5 vaccination and the associated microscopic
changes can all be attributed to the vaccine-induced antibodies.DISCUSSION
The in vivo mechanisms by which active immunization actually
protects from subsequent challenge have not been previously
analyzed microscopically for any infectious agent. Cell culture-
based assays have provided a proxy for this understanding,
but it is unclear how closely these systems mimic what is occur-
ring in the host animal (Ochsenbauer and Kappes, 2009; Se-
Thoe et al., 2000; Stanley et al., 2006). Utilizing the murine
CVC model to examine the process of in vivo HPV infection,
we recently reported that, in contrast to what is described for
cultured cell infection, the initial steps for in vivo HPV infection
take place on the BM. These extracellular events, which involve
the transition of the mature capsid to a PC-cleaved form with
exposed L2 neutralization epitope(s), are necessary to effect
stable association with the epithelial cell surface. Here, we
have used this model to address how these characteristics of
HPV infection might contribute to the mechanisms of protection
induced by the current HPV L1 VLP vaccine and a candidate L2
vaccine, thus providing a mechanistic examination of antibody-
dependent inhibition of virus infection in vivo.
To examine vaccine-induced protection from PV infection
in vivo, we compared capsid binding, localization, and L2
epitope exposure in control animals with those either immunized
with VLPs or receiving passively transferred L1-immune serum.
The latter approach allows us to analyze the inhibition of infection
at various quantities of virion-specific antibodies. Through these
analyses, we have identified two distinct mechanisms of inhibi-
tion mediated by polyclonal antibodies against L1, with the
predominant mechanism depending upon antibody level. As dis-
cussed below, some aspects of these mechanisms were not
predicted from cell culture models. A model summarizing these
mechanisms is presented in Figure 7. The events observed in
unimmunized animals are shown in Figure 7A. In contrast,
prevention of infection mediated by VLP-vaccination or transferrabbit anti-L2 serum, which was detected with an Alexa Fluor 488-conjugated
donkey anti-rabbit secondary antibody (green). Complete blocking of the
low-volume passive transfer was achieved. The omission of the anti-L2 serum
but inclusion of the Alexa Fluor 488-conjugated donkey anti-rabbit secondary
antibody resulted in no detectable signal (H). The experiment could not be
performed with the high-volume passive transfer due to the inability to achieve
complete blocking (data not shown).
Images are representative of five animals tested for each condition examined.
See also Figures S1, S2, and S3.
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Figure 5. Capsid Localization and L2 Exposure following L2
Immunization
(A–D) Capsid binding and localization were examined in mice that had been
immunized with the L2 11–88x5. HPV16 capsid binding was examined at
4 hr (A) and 18 hr (B) postinstillation (green). Likewise, HPV45 capsid binding
was examined at 4 hr (C) and 18 hr (D). Rabbit anti-L1 serum against the
appropriate type was used for staining in order to show capsid localization.
Images are representative of five animals tested for each condition examined.
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We postulate that a high antibody-to-virus particle ratio results in
an immunoglobulin-coated capsid, which effectively precludes
the interaction of the capsid proteins with HSPG on the BM,
the required first step in infection. The soluble virion/antibody
complexes are subsequently scavenged by neutrophils possibly
through opsonization. However, we cannot rule out the possi-
bility that some virion/antibody complexes transiently associate
with the BM prior to rapid removal by infiltrating neutrophils.
By contrast, low concentrations of serum that are still strongly
protective against infection only partially prevent BM binding
(Figure 7C). However, engagement of the secondary L1 receptor
on the epithelial cell surface by the capsid is prevented, and the
virus is lost from the tissue. Based on the results with neutralizing
monoclonal antibodies on cultured cells, we had previously
hypothesized that low amounts of L1 antibodies might neutralize
by cross-linking the capsomers, thereby preventing a concerted
conformational change in the capsid required for exposure of the
L2 N terminus to furin cleavage (Day et al., 2007). However, our
current results clearly demonstrate that the L2 17–36 epitope is
exposed on BM in vivo in the presence of low concentrations
of neutralizing antibodies. Therefore, it seems likely that low
concentrations of antibodies function by direct inhibition of
capsid interaction with the secondary keratinocyte-specific
receptor. Inhibition of this interaction might require fewer
capsid-bound antibodies than are necessary to block binding
to HSPG on the BM. It is also possible that, under conditions266 Cell Host & Microbe 8, 260–270, September 16, 2010 ª2010 Elsof low antibody occupancy, an additional undefined conforma-
tional change is prevented that is essential for epithelial cell
transfer.
Both of the mechanisms of L1-based neutralization observed
in this study are likely to be relevant to protection of VLP-vacci-
nated women, as the initially high peak titers observed after
the standard three-dose regimen decline rapidly in the first 1 to
2 years and then plateau at a 20- to 100-fold lower level (Olsson
et al., 2007; Romanowski et al., 2009). The striking similarity of
peak titers and of the type restriction of protection seen in our
model after L1 VLP vaccination and the degree seen in clinical
trials of HPV VLP vaccines make it likely that the results obtained
herein are relevant to cervicovaginal HPV infections in women.
Moreover, they suggest that the long duration of protection
seen with vaccination may be more attributable to the inhibition
mechanism seen at lower antibody levels.
Following L2 vaccination, we observed near normal levels of
BM association of both homologous and heterologous types.
This result was not unexpected, as we have previously demon-
strated that the major L2 neutralization epitope(s) are poorly
exposed in mature capsids and become exposed gradually on
the BM (Kines et al., 2009). Therefore, the anti-L2 antibodies
would bind inefficiently to the input capsids. However, following
deposition on the BMand PC cleavage, anti-L2 antibodies would
be able to bind to their newly exposed target epitope(s). We
speculate that antibody-bound capsids fail to stably engage
the epithelial cell surface because L2 antibody binding sterically
hinders engagement of the keratinocyte-specific receptor. This
receptor would normally be bound via a surface of L1 that is
exposed after PC cleavage of L2 (compare Figures 7A and
7D). The loss of the virions from the BM mediated by anti-L2
antibodies might indicate that the conformational change
leading to exposure of the L2 cross-neutralization epitope(s)
also results in a reduced affinity for HPSG. Of interest, the
protective antibodies induced by the L2 vaccine lead to changes
that are microscopically similar to those seen at low concentra-
tions of the anti-L1 VLP serum, although the epitopes bound by
the respective antibodies are clearly distinct. It is encouraging to
L2 vaccine prospects that protection may be induced by the
same mechanism possibly responsible for long-term protection
following VLP vaccination.
Important aspects of these results were not predicted from the
analysis of neutralization mechanisms in cultured cells, further
underscoring the utility of the in vivo analysis. These differences
arise in part because, in immortalized cultured cells, HPV can
directly bind either to HSPG on the cell surface or to non-HSPG
ECM determinants, whereas, in vivo, there appears to be a strict
initial binding to BM-associated HSPG. This understanding, in
fact, minimizes the apparent discrepancies between the in vivo
and in vitro observations for L2 neutralization. In cultured kerati-
nocytes, we found that, following HSPG-mediated cell surface
association, the L2 cross-neutralization epitope was exposed
and that antibody engagement prevented transfer to the
secondary cell surface receptor. This caused a loss of capsids
from the cell surface and sequestration on the ECM. The exis-
tence of this additional capsid binding site in vitro leads to reten-
tion of the neutralized capsids in the cell culture system. More
substantive differences are obvious when comparing the anti-
L1 neutralization mechanisms. For example, the same rabbitevier Inc.
Figure 6. Localization of Capsids following
Passive Transfer of Anti-L2 Sera
Rabbit anti-L2 immune serum was passively
transferred into mice, and the localization of
capsids was analyzed at either 4 hr (A, B, D, E,
G, H, and K) or 18 hr (C, F, I, and L) following
delivery. (A)–(F) show localization of HPV16.
(G)–(L) show localization of HPV45. The capsid-
antibody complexes at 4 hr were detected with
Alexa Fluor 488-conjugated donkey anti-rabbit
(green) in (A), (D), (G) and (J), showing weak stain-
ing of the antibody-capsid complexes following
either transfer of high volume (A and G) or low
volume (D) of immune serum. Visualization of
anti-L2 bound to HPV45 capsids in the low-
volume transfer was below the threshold of
detection (J). Detection of capsids (instead of
antibody-bound capsids) with anti-L1 serum is
shown for the same sections in the adjacent
panels (B, E, H, and K). Detection of capsids with
the anti-L1 serum at 18 hr is shown in (C) for
high-volume HPV16; (F) for low-volume HPV16;
(I) for high-volume HPV45; and (L) for low-volume
HPV45. Images are representative of five animals
tested for each condition examined. See also
Figure S1.
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Prevention of In Vivo HPV Infectionpolyclonal serum that at high concentrations prevents virus from
binding to HSPG on the BM in vivo blocks ECMbinding, but does
not affect association of the virus with cell surface HSPG on
cultured cells. Instead, this serum prevents infection by inter-
fering with the stable engagement of the virus with the secondary
cell surface receptor and subsequent endocytosis. This in vitro
result is unchanged whether neutralizing with high concentra-
tions or low concentrations of serum. In the in vitro assay, the
main difference observed between the two concentrations is
that the L2 17–36 epitope is exposed at the low concentration,
but not at the high concentration, of serum. The binding of
high-occupancy virion/antibody complexes to cultured cells,
but not the BM, could have several explanations. Modifications
of HSPG on cell surfaces and ECM have been shown to differ
even within the same cell type (Stow and Farquhar, 1987). The
HSPG composition of the in vivo BM is likely to be even more
complex, as it arises frommultiple cell types. Therefore, the rela-Cell Host & Microbe 8, 260–270, Setive affinity of the antibody and different
forms of HSPG for a common or overlap-
ping binding site on the capsid could
account for the difference. In addition, it
has been hypothesized that there may
be more than one HSPG binding site on
the capsids (Selinka et al., 2007). Anti-
bodies that block the capsid determinant
that binds BM-like HSPGon cellsmay not
block the site that binds to a second class
of cell surface HSPG.
A noteworthy feature of the candidate
L2 vaccine, L2 11–88x5, is that it targets
cryptic cross-neutralization epitopes.
Our challenge studies demonstrate broad
cross-protection against all HPV typestested, including those not present in this L2 immunogen. This
result provides important reassurance that the remarkably broad
cross-neutralizing activity previously observed with in vitro
neutralization assays is not an artifact that might result from
the substantial differences in the initial events of infection that
occur in vivo versus in vitro. Other viruses, such as HIV, expose
cryptic functional domains transiently after cell surface attach-
ment, thereby limiting the opportunity to induce neutralizing
antibodies directed against them (Zwick and Burton, 2007).
Thus, the theoretical advantage that targeting cryptic epitopes
could result in the induction of broadly protective antibodies is
usually outweighed by the joint challenges of generating a strong
immune response to such epitopes and the brief exposure of the
epitopes during infection (Haynes and Montefiori, 2006; Kelker
et al., 2010). L2 may represent an exceptional opportunity for
success because the cryptic L2 epitopes are exposed for several
hours while the virus resides on the BM.ptember 16, 2010 ª2010 Elsevier Inc. 267
Figure 7. Model of HPV Binding and Inter-
ference by Vaccine-Induced Antibodies
(A–D) (A) depicts normal in vivo binding, cleavage,
and transfer of the virion to the epithelial cell
surface. BM binding is blocked in the presence
of high concentrations of anti-L1 antibodies (B);
however, at low concentrations (C), anti-L1 anti-
bodies prevent stable engagement of the cell
surface receptor. Anti-L2 antibodies bind only
after the initial conformation change on the BM
and cleavage of L2 by furin or PC5/6 (D) and also
prevent stable binding to the cell surface.
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Prevention of In Vivo HPV InfectionThe demonstration that passive systemic transfer of anti-L1
VLP or anti-L2 immune sera can protect mice from cervicovagi-
nal challenge confirms two concepts related to the mechanism
of action of prophylactic HPV vaccines and provides an
approach to test the protective activity of any sera. First,
because the results observed after passively administering
sera from immunized animals recapitulate both the protection
and the microscopic appearance following direct vaccination,
they provide formal proof that antibodies mediate the predomi-
nant protective activity of both vaccines. Second, following
vaccination, the possibility that some of the virus-specific
antibodies in the genital tract are locally produced by mucosal
antibody-secreting B cells cannot be formally eliminated.
However, the passive serum transfer results directly confirm
that systemic circulating vaccine-induced antibodies are
capable of preventing HPV infection of the female genital tract,
either by exudation at the site of trauma or transudation into
the cervicovaginal mucus. Finally, the reproducible effectiveness
of passively transferred sera in the prevention of genital tract
HPV infection raises the possibility that this assay could be268 Cell Host & Microbe 8, 260–270, September 16, 2010 ª2010 Elsevier Inc.used to derive a surrogate immune corre-
late of protection for the sera collected
from clinical vaccination trials. We plan
to evaluate this possibility.
EXPERIMENTAL PROCEDURES
Pseudovirions
HPV16 L1 VLPs used for immunization were
prepared as described in Harro et al. (2001). All
pseudovirions were produced as previously
described (Buck and Thompson, 2007). SDS-
PAGE analysis was performed to determine the
concentration of the HPV16 L1 content of the
pseudovirus preparation. For those experiments
requiring fluorescently labeled pseudovirus, after
Optiprep purification, particles were conjugated
to Alexa Fluor 488 according to manufacturer’s
protocol (Invitrogen) and then placed over a
second Optiprep gradient to remove unconju-
gated fluorophore.
Animal Studies
Six- to eight-week-old female BALB/cAnNCr mice
were obtained from the National Cancer Institute
and housed and handled in accordance with the
NCI-approved guidelines. Experimental protocols
were approved by the National Cancer Institute’s
Animal Care and Use Committee. Animals wereimmunized subcutaneously with 5 mg of 16L1 VLPs or 25 ug of 6His-tagged
L2 11–88x5 peptide (Jagu et al., 2009) precipitated onto Imject Alum (Thermo)
to a final volume of 100 ml. Animals were immunized three times, with each
injection spaced 2 weeks apart. Anti-L1 rabbit serum (in vitro EC50 =
1:10,950,000) used in the passive transfer studies was obtained from a 16L1
VLP-immunized rabbit and has been previously described (Roden et al.,
1996). Anti-L2 polyclonal rabbit serum (in vitro EC50 = 1:20,605) was similarly
generated against the L2 11–88x5 peptide.
In Vivo Pseudovirus Delivery and Infection
The mice were exposed to male mouse bedding for 7 days and received 3 mg
of Depo-provera (Pfizer) 5 days prior to infection (Johnson et al., 2009).
Animals were pretreated with 4% nonoxynol-9 and subsequently infected
with pseudovirus as previously described (Cuburu et al., 2009; Johnson
et al., 2009; Roberts et al., 2007). A PsV inoculum of 10 mg, based on L1
content, was used regardless of type in order to equalize the potential number
of target epitopes for the neutralizing antibodies. The particle-to-infectivity
ratio varies among types, thus explaining the difference in luminescent signal
observed for the positive controls. For those mice receiving the passively
transferred rabbit serum, serum was delivered neat or diluted in 13PBS to
a final volume of 100 ml and was administered intraperitoneally 24 hr prior
to infection. Infection was measured 48 hr after pseudovirus delivery as
previously described (Cuburu et al., 2009; Johnson et al., 2009). Raw data
Cell Host & Microbe
Prevention of In Vivo HPV Infectionwere computed using Living Image software (Caliper Life Sciences). An iden-
tical region of interest (ROI) was drawn around the luciferase signal emitted
from each mouse, and the average radiance within the ROI was determined.
For binding analyses, mice were sacrificed at 4 or 18 hr following pseudovirus
instillation, and tissues were treated as described in Kines et al. (2009).
Antibodies and Immunofluorescent Staining
The rabbit polyclonal antiserum against HPV16 L1, the rat anti-HPV16 L1 poly-
clonal serum, and the rabbit antiserum, 17/36, that recognizes aa17–36 of L2
were previously described (Kines et al., 2009). The rat anti-nidogen mono-
clonal antibody was obtained from US Biological. Neutrophils were detected
with a rat anti-neutrophil antibody (Santa Cruz Biotechnology). Tissues were
stained as previously described (Kines et al., 2009). For L2 17–36 detection
following passive transfer of the low volume of rabbit immune VLP serum, it
was necessary to first prevent detection of the input serum by blocking with
unlabeled donkey anti-rabbit serum. Complete blocking was confirmed by
detection with Alexa Fluor 488-coupled donkey anti-rabbit serum. The 17/36
antiserum was then used for specific detection of the L2 epitope without
interference from the delivered serum. Following staining, all sections were
mounted with Prolong Gold mounting solution (Invitrogen). Microscopy was
performed on a Zeiss LSM 510 confocal system interfaced with a Zeiss
Axiovert 100M microscope. Images were collated with Adobe Photoshop
software.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism Software, in which
a one-tailed unpaired t test was used to determine p values.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at doi:10.1016/
j.chom.2010.08.003.
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